BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2017 9:08:00 AM | Browse: 920 | Download: 1762
 |
Received |
|
2016-07-06 09:49 |
|
Peer-Review Started |
|
2016-07-09 15:17 |
|
To Make the First Decision |
|
2016-09-07 14:53 |
|
Return for Revision |
|
2016-09-09 16:43 |
|
Revised |
|
2016-10-12 00:42 |
|
Second Decision |
|
2016-12-07 16:35 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2016-12-14 16:45 |
|
Articles in Press |
|
2016-12-14 16:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-01-22 11:49 |
|
Publish the Manuscript Online |
|
2017-02-06 09:08 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A Butt and the ACTG 5294 BIRTH Study Team |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kenneth E Sherman, MD, PhD, Gould Professor of Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, United States. kenneth.sherman@uc.edu |
| Key Words |
human immunodeficiency virus; hepatitis C virus; Boceprevir; Pegylated interferon alfa; Ribavirin |
| Core Tip |
Approval of first generation hepatitis C virus (HCV) protease inhibitors has initiated a change in care of HCV infected patients. Phase 2 trials in HCV/human immunodeficiency virus coinfected patients have sug-gested improved efficacy and tolerability for regimens that combined pegylated interferon (PEG-IFN) + ribavirin (RBV) with either boceprevir or telaprevir. We evaluated an HCV treatment regimen using a first generation HCV protease inhibitor (boceprevir) with PEG-IFN, and weight-based RBV in a phase 3 treatment trial, including HCV treatment-na?ve and treatment-experienced coinfected subjects. While sustained viral response rates were low overall they did exceed historical PEG-IFN/RBV rates. Use of new interferon-free direct acting antiviral agents modalities in this population is indicated. |
| Publish Date |
2017-02-06 09:08 |
| Citation |
Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 2017; 9(4): 217-223 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i4/217.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i4.217 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
